Boston, Massachusetts, United States
Gabriel Corfas, M. Charles Liberman
2015
Private company
NASDAQ:DBTX
IPO
389
The Longevity Fund, BlackRock, SR One, S-Cubed Capital, Casdin Capital, GV, Foresite Capital, Sobrato Capital, Third Rock Ventures
Cell Loss
Cisplatin Ototoxicity, Otogerlin Deficiency, Age Related Balance Dysfunction, Sensorineural Hearing Loss
gene therapy
Phase 1 Trials
DB-O20
Decibel Therapeutics, a clinical-stage biotechnology company, has established the world’s first comprehensive drug discovery, development, and translational research platform for hearing and balance disorders. Decibel’s lead therapeutic candidates, DB-020 and DB-041, are designed to prevent hearing loss resulting from cisplatin and aminoglycoside antibiotics, respectively. Decibel is also advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibel is headquartered in Boston, Mass. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow @DecibelTx on Twitter